Trial · NCT03001011
Results by group124
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 124
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Serum Phosphorus at Week 8 | Placebo | Baseline | 2.090 | Full Range 1.870 to 2.270 | mmol/L |
| Change From Baseline in Serum Phosphorus at Week 8 | Renvela | Baseline | 2.095 | Full Range 1.870 to 2.400 | mmol/L |
| Change From Baseline in Serum Phosphorus at Week 8 | Placebo | Change at Week 8 | 0.010 | Full Range -0.200 to 0.250 | mmol/L |
| Change From Baseline in Serum Phosphorus at Week 8 | Renvela | Change at Week 8 | -0.200 | Full Range -0.490 to 0.020 | mmol/L |
| Change From Baseline in Total Cholesterol at Week 8 | Placebo | -0.115 | Full Range -1.82 to 1.54 | mmol/L | |
| Change From Baseline in Total Cholesterol at Week 8 | Renvela | -0.830 | Full Range -4.45 to 0.74 | mmol/L | |
| Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 | Placebo | -0.030 | Full Range -1.61 to 1.30 | mmol/L | |
| Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 | Renvela | -0.830 | Full Range -3.31 to 0.51 | mmol/L | |
| Change From Baseline in Calcium-Phosphorus Product at Week 8 | Placebo | 0.0200 | Full Range -2.648 to 2.936 | mmol^2/L^2 | |
| Change From Baseline in Calcium-Phosphorus Product at Week 8 | Renvela | -0.4960 | Full Range -2.592 to 2.696 | mmol^2/L^2 | |
| Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8 | Placebo | 7.2380 | Full Range -298.732 to 573.306 | nanogram per liter (ng/L) | |
| Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8 | Renvela | 0.0000 | Full Range -370.172 to 327.966 | nanogram per liter (ng/L) | |
| Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8 | Placebo | 6.6 | percentage of participants | ||
| Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8 | Renvela | 15.5 | percentage of participants | ||
| Change From Baseline in Serum Phosphorus Level at Week 4 | Placebo | -0.020 | Full Range -1.56 to 2.42 | mmol/L | |
| Change From Baseline in Serum Phosphorus Level at Week 4 | Renvela | -0.240 | Full Range -1.03 to 1.39 | mmol/L | |
| Number of Participants With Treatment Emergent Adverse Event | Placebo | Any TEAE | 86 | Participants | |
| Number of Participants With Treatment Emergent Adverse Event | Renvela | Any TEAE | 83 | Participants | |
| Number of Participants With Treatment Emergent Adverse Event | Placebo | Any Treatment emergent SAE | 31 | Participants | |
| Number of Participants With Treatment Emergent Adverse Event | Renvela | Any Treatment emergent SAE | 26 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03001011/results